- Open Access
The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study
Thrombosis Journal volume 20, Article number: 8 (2022)
The authors have done commendable work in exploring the utility of a comprehensive viscoelastic test for assessment of the coagulation cascade in Coronavirus disease 2019 (COVID-19) patients. This article published in your esteemed journal in November 2021 “The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study” found hypercoagulability in most of the patients at Intensive Care Unit (ICU) admission and also noted a persistently increased fibrin contribution to clot strength. However, we would like to comment upon a few points which may be of importance to the readers.
We read with great interest the article published by Neethling C et al in your esteemed journal in November 2021 issue, entitled “The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study”.  The authors have done commendable work to explore the utility of thromboelastography, a comprehensive test for assessment of the coagulation cascade, in Coronavirus disease 2019 (COVID-19) patients with severe Acute Respiratory Distress syndrome (ARDS) requiring mechanical ventilation. In this study, hypercoagulability was found in the majority of patients at Intensive Care Unit (ICU) admission, which was also noted in a recent study by Fan BE et al . These findings may be the reason behind microthrombosis, often seen in COVID-19 associated coagulopathy.. In addition, it is worth appreciating that the authors have given importance to the assessment of clot stability by analyzing the fibrinolytic pathway, wherein a persistently increased fibrin contribution to clot strength was noticed. A similar concept of accentuated hypercoagulability secondary to fibrinolytic shutdown was highlighted by Coccheri S et al in 2020 
However, a few comments which we would like to add are:
It is difficult to explicitly differentiate whether the changes in clot strength were mediated by a cross talk between ARDS and coagulation, signifying an interplay between inflammation and coagulation, or by COVID severity per se. 
Most of the patients were obese (BMI > 30 Kg/m2),  which may itself contribute to hypercoagulability
Although patients with predisposition to thrombosis (like malignancy and pregnancy) were excluded from this study,analyzing how COVID-19 affects the changes in clot strength and composition in this subgroup may be an area of future research.
Influence of medications like antiplatelets and antifibrinolytics on TEG profile is not clear from the study.
Baseline values of TEG may be different for different populations  and these values may also vary for different TEG machines  as has been seen in a recent study in COVID-19.
Disposal of COVID-19 positive blood and disinfection of TEG machine would also be prudent to know for the readers interested in replicating similar studies.
Follow up period was for first 2 weeks only and the 14-30 day follow up period was missing in patients. It may be possible that the non-survivors had eventually progressed to a hypocoagulable TEG profile,  which has been associated with poor outcome in studies.
Only half of the patients (21/40) could be followed up serially over the 2 week observation period, which may not truly reflect dynamicity of changes in TEG parameters in survivors versus non-survivors in COVID patients and may require more studies in this area.
Availability of data and materials
The relevant references have been taken from either Pubmed or Google scholar. Doi links to the references have been attached.
Neethling C, Calligaro G, Miller M, Opie JJS. The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study. Thromb J. 2021;19(1):83. https://doi.org/10.1186/s12959-021-00331-5.
Fan BE, Ramanathan K, Sum CLL, et al. Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study. J Thromb Thrombolysis. 2021:1–17. https://doi.org/10.1007/s11239-021-02575-4.
Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8:e524–33. https://doi.org/10.1016/S2352-3026(21)00105-8. Epub 2021.
Coccheri S. COVID-19: The crucial role of blood coagulation and fibrinolysis. Intern Emerg Med. 2020;15:1369–73. https://doi.org/10.1007/s11739-020-02443-8. Epub 2020.
Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration. 2017;93(3):212–25. https://doi.org/10.1159/000453002.
Bruni-Fitzgerald KR. Review of article: obesity and clotting: BMI independently contributes to hypercoagulability after injury. J Trauma Acute Care Surgery. 2015;78(1):30-38. J Vasc Nurs. 2018;36(4):216–7. https://doi.org/10.1016/j.jvn.2018.10.001.
Muzaffar SN, Azim A, Siddiqui SS. Re: thromboelastograph: a prognostic marker in sepsis with organ dysfunction without overt bleeding. J Crit Care. 2021:S0883-9441(21)00190-8. https://doi.org/10.1016/j.jcrc.2021.09.003.
Infanger L, Dibiasi C, Schaden E, Ulbing S, Wiegele M, Lacom C, et al. Comparison of the new viscoelastic coagulation analyzer ClotPro® with ROTEM® delta and conventional coagulation tests in critically Ill patients with COVID-19. Front Med (Lausanne). 2021;8:777145. https://doi.org/10.3389/fmed.2021.777145.
Ninan KF, Iyadurai R, Varghese JK, Geevar T, Nair SC, Yadav B, et al. Thromboelastograph: a prognostic marker in sepsis with organ dysfunction without overt bleeding. J Crit Care. 2021;65:177–83. https://doi.org/10.1016/j.jcrc.2021.06.005. Epub 2021.
We would like to thank Professor Shakti Bedanta Mishra, Department of Critical Care, IMS & SUM Hospital, Bhubaneshwar, India for his help extended in writing this manuscript.
The authors declare no funding involved.
Ethics approval and consent to participate
Consent for publication
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Muzaffar, S.N., Siddiqui, S.S., Chakraborty, N. et al. The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study. Thrombosis J 20, 8 (2022). https://doi.org/10.1186/s12959-022-00365-3
- Thromboelastography (TEG)